Biotech RadarJobs updated

COMPANY

Dendreon

HQ: Seattle, WA source · dendreon.com ↗

Status: Acquired, now part of Nanjing Xinjiekou Department Store (Cenbest) · How status works

FDA-approved therapeutic company Clinical Phase 3

7 open jobs · last seen Oct 23, 2026 · 21 sources

Keywords: oncology Prostate Cancer Prostatic Neoplasms Castration-Resistant Prostate Cancer Hormone Refractory Prostate Cancer Prostate Neoplasms Metastatic Castration-Resistant Prostate Cancer Adenocarcinoma of the Prostate Metastatic Androgen Independent Prostate Cancer Advanced Prostate Cancer Prostate Cancer Metastatic Metastatic Prostate Cancer Prostatic Adenocarcinoma Urothelial Carcinoma Cancer of Prostate Cancer of the Prostate Prostatic Cancer sipuleucel-T APC8015F DN24-02

Location: Seal Beach, CA · source · Oct 13, 2026

Other sites: Seattle, WA (medical affairs, operations, research sciences) source source · Union City, GA (commercial immunotherapy manufacturing) source

Profile checked Oct 10, 2026

7Open jobs20Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Executive Director, Business Development & Corporate StrategySeal Beach, California, United StatesOct 16, 2026Oct 17, 2026
Key Account Manager - Upstate New YorkNew York; Remote, USAOct 13, 2026Oct 14, 2026
Manager, Sourcing & ProcurementSeal Beach, California, United StatesOct 8, 2026Oct 9, 2026
Director, Clinical OperationsSeal Beach, California, United StatesSep 23, 2026Oct 5, 2026
Payroll Clerk IISeal Beach, California, United StatesSep 17, 2026Oct 5, 2026

See all 7 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (7 open jobs at last check). source ↗
  2. Trial start Phase 2: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T source ↗
  3. Trial start Phase 3: Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer source ↗
  4. Trial start Phase 2: A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer source ↗
  5. Trial start —: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T source ↗
  6. Trial start Phase 2: Sipuleucel-T Manufacturing Demonstration Study source ↗
  7. Trial start —: Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer source ↗
  8. Trial start Phase 2: Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer source ↗
  9. Trial start Phase 2: Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer source ↗
  10. Trial start Phase 2: Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer source ↗
  11. Trial start Phase 2: DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma source ↗
  12. Trial start —: A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer source ↗
  13. Trial start Phase 2: Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer source ↗
  14. Trial start Phase 1: Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors source ↗
  15. Trial start Phase 2: To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen source ↗
  16. Trial start Phase 2: Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer source ↗
  17. Trial start Phase 2: Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) source ↗
  18. Trial start Phase 3: Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy source ↗
  19. Trial start Phase 3: PROvenge Treatment and Early Cancer Treatment source ↗
  20. Trial start Phase 3: Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer source ↗
  21. Trial start Phase 3: Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 7

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Executive Director, Business Development & Corporate StrategySeal Beach, California, United StatesOct 16, 2026Oct 17, 2026Not stated
Key Account Manager - Upstate New YorkNew York; Remote, USAOct 13, 2026Oct 14, 2026Mid
Manager, Sourcing & ProcurementSeal Beach, California, United StatesOct 8, 2026Oct 9, 2026Mid
Director, Clinical OperationsSeal Beach, California, United StatesSep 23, 2026Oct 5, 2026Senior
Payroll Clerk IISeal Beach, California, United StatesSep 17, 2026Oct 5, 2026Mid
Manager, Regulatory AffairsSeal Beach, California, United StatesSep 8, 2026Oct 5, 2026Senior
Vice President, Medical Affairs, Clinical Operations & Regulatory AffairsSeal Beach, California, United StatesAug 14, 2026Oct 5, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 20

RecordTitlePhaseStatusStartPrimary completion
NCT06134232Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TPhase 2RecruitingOct 2, 2023Dec 31, 2031 (estimated)
NCT03686683Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerPhase 3CompletedOct 18, 2018Mar 10, 2023 (actual)
NCT00849290Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)Phase 2Completed2004-042009-01 (actual)
NCT01981109Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate CancerNot listedTerminated2012-012017-07 (actual)
NCT01727154Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-TNot listedTerminated2012-102017-07 (actual)
NCT01306890A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate CancerNot listedCompletedJan 27, 2011Jan 17, 2017 (actual)
NCT01487863Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerPhase 2Completed2011-122016-05 (actual)
NCT01981122A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerPhase 2Completed2013-09Jun 30, 2017 (actual)
NCT00779402PROvenge Treatment and Early Cancer TreatmentPhase 3Completed2001-102006-08 (actual)
NCT01338012Sipuleucel-T in Metastatic Castrate Resistant Prostate CancerPhase 2Terminated2011-122015-04 (actual)
NCT01431391Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate CancerPhase 2Completed2011-092014-12 (actual)
NCT01353222DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial CarcinomaPhase 2Terminated2011-062015-07 (actual)
NCT00901342Open Label Study of Sipuleucel-T in Metastatic Prostate CancerPhase 2Completed2009-102014-12 (actual)
NCT00715078To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) AntigenPhase 2Completed2008-102012-04 (actual)
NCT01477749Sipuleucel-T Manufacturing Demonstration StudyPhase 2Completed2012-062014-06 (actual)
NCT00715104Sipuleucel-T as Neoadjuvant Treatment in Prostate CancerPhase 2Completed2008-072012-12 (actual)
NCT00839631Dose Escalation Study of EC D-3263 HCl in Advanced Solid TumorsPhase 1Completed2009-032011-12 (actual)
NCT00005947Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyPhase 3Completed1999-112004-09 (actual)
NCT01133704Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate CancerPhase 3Completed2000-052003-03 (actual)
NCT00065442Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyPhase 3Completed2003-072009-01 (actual)
Feedback